Evaluation of Silverlon Dressing for Autogenous Skin Donor Sites
- Conditions
- Burns
- Interventions
- Device: Silverlon
- Registration Number
- NCT00137215
- Lead Sponsor
- United States Army Institute of Surgical Research
- Brief Summary
The purpose of this study is to compare one type of dressing against the current standard dressing that is used to cover an unburned area of the skin where a piece of skin is removed to cover another part of the body that was burned.
Hypothesis: The mean healing time for wounds treated with the Silverlon Dressing will be less than the mean healing time for wounds treated with Xeroform Dressing.
- Detailed Description
At the time of the procedure, donor sites that are symmetrical in size and shape will be selected. Once the grafts have been harvested, the wounds will be randomized for treatment using either the Silverlon dressing or Xeroform. The wound dressings will then be observed at least once a day beginning 72 hours after surgery until healed, defined as 90% or more of the wound surface being confluently re-epithelized.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
- 18 years or older; male or female.
- Burn wounds of less than 30% total body surface area (TBSA) with no systemic abnormalities
- Burns do not involve the harvesting area
- Burn wounds require excision and grating of sufficient extent to justify two donor sites of equal and symmetrical size on non-dependent body surface areas
- Scheduled excision and grafting procedures is the first such operation for subject during this hospitalization
- Subject agrees to participate in follow-up evaluations
- Critical illnesses requiring ventilator support, systemic infection or hemodynamic instability
- Major acute or chronic illnesses affecting wound healing (e.g. peripheral vascular disease, insulin dependent diabetes, blood clotting disorder)
- Subject receiving medications that inhibit/compromise wound healing (e.g. anticoagulants, antiplatelet drugs, oral steroids). The use of anticoagulants does not include deep vein thrombosis (DVT) prophylaxis.
- Cellulitis or other infection of potential donor site
- Previously harvested donor site
- Subject with greater than 30% TBSA burns
- Subjects with sensitivity to silver or nylon
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A Silverlon -
- Primary Outcome Measures
Name Time Method Pain will be less than or equal to with the Silverlon Dressing as compared with Xeroform 14 days Cosmetic effect of healing at post operative day 30-45 will be equal to or less than with Silverlon as compared with Xeroform 30-45 days
- Secondary Outcome Measures
Name Time Method Infections associated with donor sites will be equal to or less than with Silverlon as compared with Xeroform 14 days
Trial Locations
- Locations (1)
US Army Institute of Surgical Research
🇺🇸Fort Sam Houston, Texas, United States